Tanis, J-B, Mason, SL, Maddox, TW, Blackwood, L, Killick, DR ORCID: 0000-0002-8787-7651, Amores-Fuster, I, Harper, A and Finotello, R ORCID: 0000-0002-1932-211X
(2018)
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
VETERINARY AND COMPARATIVE ONCOLOGY, 16 (3).
pp. 361-369.
This is the latest version of this item.
Text
LPP final.pdf - Author Accepted Manuscript Available under License : See the attached licence file. Download (259kB) |
Abstract
The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP). Lomustine, vincristine, procarbazine, and prednisone (LOPP) has been evaluated as a rescue, with encouraging results; however, resistance to vincristine is likely in patients relapsing on CHOP/CEOP, and this agent may enhance LOPP toxicity without improving efficacy. The aim of this study was to evaluate responses to a modified-LOPP protocol that does not include vincristine (LPP) and is administered on a 21-day cycle. Medical records of dogs with high-grade multicentric lymphoma from 2012 to 2017 were reviewed. Dogs with relapsed lymphoma that received LPP as a rescue protocol were enrolled. Response, time from initiation to discontinuation (TTD) and toxicity of LPP were assessed. Forty-one dogs were included. Twenty-five dogs (61%) responded to LPP including 12 complete responses (CR) and 13 partial responses (PR). Responders had a significantly longer TTD (P < .001) compared to non-responders with 84 days for CR and 58 days for PR. Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV. Thrombocytopenia was infrequent (20%): 5 grade I to II, 2 grade III to IV. Twelve dogs developed gastrointestinal toxicity (30%): 10 grade I to II and 2 grade III. Nineteen dogs had elevated ALT (59%): 9 grade I to II, 10 grade III to IV. Treatment was discontinued due to toxicity in 8 dogs (19%). The LPP protocol shows acceptable efficacy and toxicity-profile and minimizes in-hospital procedures.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | canine lymphoma, chemotherapy, dog, lomustine, procarbazine, relapse, rescue |
Depositing User: | Symplectic Admin |
Date Deposited: | 28 Aug 2019 14:06 |
Last Modified: | 19 Jan 2023 06:42 |
DOI: | 10.1111/vco.12387 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3017149 |
Available Versions of this Item
-
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. (deposited 31 Jan 2018 07:52)
- Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. (deposited 28 Aug 2019 14:06) [Currently Displayed]